MURAT BAĞCIOĞLU, RAMAZAN KOCAASLAN, Mehmet USLU, GÜLNAME FINDIK GÜVENDİ

Böbrekte İskemi-Reperfüzyon Hasarında Ticagrelor'un Etkisi: Pleiotropik Etki Geçerli Bir Faktör mü?

Bu çalışmada, ticagrelor'un ratların böbreğinde oluşturulan iskemi-reperfüzyon hasarına karşı koruyucu etkisinin histolojik, biyokimyasal ve immünohistokimyasal yöntemler kullanılarak tanımlanması amaçlanmıştır. Bu amaçla, 30 erkek rat rastgele olarak 5 gruba ayırılmıştır. Bu hayvanlara, yapılacak işlemlerden önce ticagrelor 5 mg/kg, 10 mg/kg ve 20 mg/kg dozlarında, kontrol grubuna da 0.1 mL/kg serum fizyolojik oral olarak verilmiştir. Sham grubunda ise sadece laparatomi yapılmıştır. İskemi-reperfüzyon hasarı renal hilusun klemplenmesi yoluyla yapılmıştır. Ticagrelor verilen gruplarda saptanan malondialdehit (MDA) düzeyinin kontrol grubundan daha az olduğu ve bu düşüklüğün istatistiksel olarak anlamlı olduğu tespit edildi (tüm ticagrelor grupları için P=0.001). Glutatyonperoksidaz (GPx) ve glutatyonredüktaz (GR) düzeyleride ticagrelor verilen tüm gruplarda artmış olarak bulundu. Histopatolojik incelemelerde, tedavi verilen tüm gruplarda benzer sonuçlar gözlendi. Ancak 5 mg ticagrelor verilen grupta glomerul ve tübül yapısında kontrol grubu arasında fark olmadığı belirlendi. 10 ve 20 mg ticagrelor verilen gruplarda, sham grubuna benzer özellikte dilate tübüler yapılar olduğu gözlendi. Caspas-3 ve NF-KB aktiviteleri ticagrelor verilen gruplarda sham grubuna benzer özelliklerdeydi. Çalışmamız, ticagrelorun böbreğin iskemi-reperfüzyon hasarına karşı korunmasında etkili bir ajan olduğunu göstermiştir. Ticagrelor, pleiotropik etkisiyle reaktif oksijen türlerinin konsantrasyonunu azaltarak ve antioksidan sistemi aktive ederek dokuları koruyabilir.

The Effect of Ticagrelor on Ischemia-Reperfusion Injury of Kidney: Is the Pleiotropic Effect a Valid Factor?

The goal of this study was to determine the protective effect of ticagrelor against ischemia-reperfusion injury in the kidney of rats via histological examination, biochemical parameters, and immunohistochemical analysis. Thirty male rats were randomized into five groups. The animals received ticagrelor 5 mg/kg, 10 mg/kg and 20 mg/kg or normal saline 0.1 mL/kg (control) orally before the procedure. The shame group only had laparatomy. An ischemia-reperfusion injury was done by clamping the renal hilus. There was less malondealdehyde assay (MDA) in ticagrelor groups than the control group, and this decrease was statistically significant (P=0.001 in all ticagrelor received groups). The glutathione peroxidase (GPx) and glutathione reductase (GR) were elevated in ticagrelor groups at all doses. Similar findings were observed in all treatment groups. The 5 mg ticagrelor treated group had no changes in glomerules and tubules relative to the control group via histology. Dilated tubular structures were similar to the sham group-both at 10 and 20 mg ticagrelor. Caspas-3 and NF-KB activity was similar in ticagrelor treated groups to sham group. Our study showed that ticagrelor is an effective agent to protect kidney from renal ischemia-reperfusion injury. Ticagrelor may protect the tissues by reducing the concentration of reactive oxygen species and inducing the antioxidant system-especially with the pleiotropic effect.

PDF

___

1. Klausner JM, Paterson IS, Valeri R, Hechtman HB: Limb ischemia induced increase in permeability is mediated by leukocytes and leukotrienes. Ann Surg, 208, 755-760, 1988.
2. Klausner JM, Paterson IS, Kozbik L, Valeri R, Shepro D, Hetchtman HB: Oxygen free radicals mediate ischemia-induced lung injury. Surgery, 105, 192-199, 1989.
3. Gyurkovics E, Aranyi P, Stagnl R, Onody P, Ferreira G, Lotz G, Kupcsulik P, Szijarto A: Postconditioning of the lower limb protection against reperfusion syndrome. J Surg Res, 169, 139-147, 2011. DOI: 10.1016/ j.jss.2009.10.014
4. Carvalho AC, Guillaumon AT, Cintra Ede A, Figueiredo LC, Moreira MM, Araújo S: Plasmatic vasopressin in patients undergoing conventional infra-renal abdominal aorta aneurysm repair. Rev Bras Cir Cardiovasc, 26, 404-412, 2011. DOI: 10.5935/1678-9741.20110015
5. Catteneo M, Schulz R, Nylander S: Adenosine-mediated effects of ticagrelor. J Am Coll Cardiol, 63, 2503-2509, 2014. DOI: 10.1016/j. jacc.2014.03.031
6. Cattaneo M: The platelet P2Y12 receptor for adenosine diphosphate: Congenital and drug-induced defects. Blood, 117, 2102-2112, 2011. DOI: 10.1182/blood-2010-08-263111
7. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thorsén M: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 361, 1045-1057, 2009. DOI: 10.1056/NEJMoa0904327
8. Diehl P, Olivier C, Halscheid C, Helbing T, Bode C, Moser M: Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Basic Res Cardiol, 105, 379-387, 2010. DOI: 10.1007/s00395-009-0073-8
9. Högberg C, Svensson H, Gustafsson R, Eyjolfsson A, Erlinge D: The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. Int J Cardiol, 142, 187-192, 2010. DOI: 10.1016/j.ijcard.2008.12.091
10. Kronlage M, Song J, Sorokin L, Isfort K, Schwerdtle T, Leipziger J, Robaye B, Conley PB, Kim HC, Sargin S, Schön P, Schwab A, Hanley PJ: Autocrine purinergic receptor signalling is essential for macrophage chemotaxis. Sci Signal, 3, ra55, 2010. DOI: 10.1126/scisignal.2000588
11. Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan WB, Julius D: The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci, 9, 1512-1519, 2006. DOI: 10.1038/nn1805
12. Ben Addi A, Cammarata D, Conley PB, Boeynaems JM, Robaye B: Role of the P2Y12 receptor in the modulation of murine dendritic cell function by ADP. J Immunol, 185, 5900-5906, 2010. DOI: 10.4049/ jimmunol.0901799
13. Gachet C: P2Y12 receptors in platelets and other hematopoietic and non-hematopoietic cells. Purinergic Signal, 8, 609-619, 2012. DOI: 10.1007/s11302-012-9303-x
14. Csóka B, Németh ZH, Rosenberger P, Eltzschig HK, Spolarics Z, Pacher P, Selmeczy Z, Koscso B, Himer L, Vizi ES, Blackburn MR, Deitch EA, Hasko G: A2B adenosine receptors protect against sepsisinduced mortality by dampening excessive inflammation. J Immunol, 185, 542-550, 2010. DOI: 10.4049/jimmunol.0901295
15. Armstrong A, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ: Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther, 19, 209-219, 2014. DOI: 10.1177/ 1074248413511693
16. Van Giezen JJ, Sidaway J, Glaves P, Kirk I, Björkman JA: Ticagrelor inhibits adenosine uptake in vitro and enhances adenosinemediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther, 17, 164-172, 2012. DOI: 10.1177/1074248411410883
17. Chander V, Chopra K: Renal protective effect of molsidomine and L-arginine in ischemia-reperfusion induced injury in rats. J Surg Res, 128, 132-139, 2005. DOI: 10.1016/j.jss.2005.04.023
18. Sekhon CS, Sekhon BK, Singh I, Orak JK, Singh AK: Attenuation of renal ischemia/reperfusion injury by a triple drug combination therapy. J Nephrol, 16, 63-74, 2003.
19. Bulkley GB: Free radical-mediated reperfusion injury: A selective review. Br J Cancer Suppl, 8, 66-73, 1987.
20. Karaman A, Turkmen E, Gursul C, Tas E, Fadillioglu E: Prevention of renal ischemia/reperfusion-induced injury in rats by leflunomide. Int JUrol, 13, 1434-1441, 2006. DOI: 10.1111/j.1442-2042.2006.01592.x
21. Tugtepe H, Sener G, Biyikli NK, Yuksel M, Cetinel S, Gedik N, Yegen BC: The protective effect of oxytocin on renal ischemia/ reperfusion injury in rats. Regul Pept, 140, 101-108, 2007. DOI: 10.1016/j. regpep.2006.11.026
22. Sener G, Sehirli O, Velioglu-Ogunc A, Cetinel S, Gedik N, Caner M, Sakarcan A, Yegen BC: Montelukast protects against renal ischemia/ reperfusion injury in rats. Pharmacol Res, 54, 65-71, 2006. DOI: 10.1016/j. phrs.2006.02.007
23. Hosseini F, Naseri MK, Badavi M, Ghaffari MA, Shahbazian H, Rashidi I: Effect of beta carotene on lipid peroxidation and antioxidant status following renal ischemia/reperfusion injury in rat. Scand J Clin Lab Invest, 70, 259-263, 2010. DOI: 10.3109/00365511003777810
24. Chatterjee PK:Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: A comprehensive review. Naunyn Schmiedebergs Arch Pharmacol, 376, 1-43, 2007. DOI: 10.1007/s00210-007-0183-5
25. Korkmaz A, Kolankaya D: The protective effects of ascorbic acid against renal ischemia-reperfusion injury in male rats. Ren Fail, 31, 36-43, 2009. DOI: 10.1080/08860220802546271
26. Bozkurt Y, Fırat U, Atar M, Sancaktutar AA, Pembegul N, Soylemez H, Yuksel H, Alp H, Bodakcı MN, Hatipoglu NK, Buyukbas S: The protective effect of ellagic acid against renal ischemia-reperfusion injury in male rats. Kafkas Univ Vet Fak Derg, 18 (5): 823-828, 2012. DOI: 10.9775/ kvfd.2012.6517
27. Linden J: Molecular approach to adenosine receptors: receptormediated mechanisms of tissue protection. Annu Rev PharmacolToxicol, 41,775-87, 2001. DOI: 10.1146/annurev.pharmtox.41.1.775
28. Adamski P, Kozinski M, Ostrowska M, Fabiszak T,Navarese EP, Paciorek P, Grzesk G, Kubica J: Overview of pleitropic effects of platelet P2Y12 receptor inhibitors. TrombHaemost, 112 (2): 224-242, 2014. DOI: 10.1160/TH13-11-0915
29. Porter KA: The kidney In, Summers WC (Ed): Systemic Pathology. Vol8, 3rd edn., 491-498, Churchill-Livingstone, London,1992.